Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | STS | P08842 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL12180048 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL14373308 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL7004654 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223196 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL13123063 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL23743979 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Epiestriol SCHEMBL221084 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL223226 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL8941750 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 | |
| Estriol SCHEMBL2001122 | 1.00 | ESR1 (1.00) | ESR1ESR2LMNASHBGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| EP-2807482-B1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEV PTE LTD (SG) | 2018-03-14 | — | — | EP | claimed |
| US-9874575-B2 | Analysis of estradiol and analytes with phenolic OH using labeling chemistry and LC-MSMS workflow | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-01-23 | — | — | US | claimed |
| US-20150051111-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2015-02-19 | — | — | US | claimed |
| EP-2807482-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | Dh Technologies Development Pte. Ltd. (SG) | 2014-12-03 | — | — | EP | claimed |
| WO-2013108113-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2013-07-25 | — | — | WO | claimed |
| EP-4729935-A2 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12600700-B2 | Imidazolium reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4267951-B1 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | HOFFMANN LA ROCHE (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4153565-B1 | BENZYLPYRIDINIUM REAGENT FOR MASS SPECTROMETRY | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-3577466-B1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2026-01-07 | — | — | EP | disclosed |
| WO-2013108113-A1 | ANALYSIS OF ESTRADIOL AND ANALYTES WITH PHENOLIC OH USING LABELING CHEMISTRY AND LC-MSMS WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2013-07-25 | — | — | WO | disclosed |
| WO-2008147640-A2 | HORMONE REPLACEMENT THERAPY | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20060035875-A1 | Remedy for hormone-dependent cancer | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060014973-A1 | Processes for the preparation of 16beta-alkoxy, 17alpha-hydroxy steroids and steroidal 16beta, 17alpha-diols from 16alpha, 17alpha-epoxy steroids | WYETH (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1568381-A1 | REMEDY FOR HORMONE-DEPENDENT CANCER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035875-A1 | Remedy for hormone-dependent cancer | STS, CYP21A2, SHBG | ESR1 215/4885ESR2 235/4885LMNA 4511/4885 |
| US-20060014973-A1 | Processes for the preparation of 16beta-alkoxy, 17alpha-hydroxy steroids and steroidal 16beta, 17alpha-diols from 16alpha, 17alpha-epoxy steroids | HSD17B7, HSD11B1, HSD3B1 | ESR1 156/4885ESR2 127/4885LMNA 949/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | ESR1 1524/4885ESR2 409/4885LMNA 344/4885 |
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | ESR1 4/4885ESR2 1/4885LMNA 4487/4885 |
| US-12600700-B2 | Imidazolium reagent for mass spectrometry | SRMS, PTMS, F2 | ESR1 531/4885ESR2 614/4885LMNA 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.